Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 6

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 6
---
 Nasdaq to effect the additional listing of NLS Common Shares issuable in connection with the Merger. NLS has applied to have the common shares of the surviving company trade on the Nasdaq after completion of the Merger, under NLS’s new name, NewcelX Ltd., and new trading symbols for its Common Shares and traded warrants, “NCEL” and “NCELW”, respectively. NLS is holding the NLS Meeting of its shareholders for the following purposes, as more fully described in the accompanying proxy statement: 1.To approve, on an advisory basis, the Merger Agreement. 2.To approve (i) the reduction of the par value from CHF 0.03 per NLS Common Share, per preferred share of the Company (each a “Preferred Share”), and per Preferred Participation Certificate of the Company (each a “PPC”), to (not less than) CHF 0.003 per NLS Common Share, per Preferred Share and per PPC, and book any reduction amount into capital contribution reserves, (ii) the increase of the share capital and the participation capital by such minimum number of NLS Common Shares, Preferred Shares, and PPCs that allows the reverse split under Proposal 2(iii) to take place without fractional Common Shares, Preferred Shares, and PPCs against payment on behalf of the Company of the nominal amount and with exclusion of subscription rights of the shareholders, (iii) the reverse split of the Ordinary Shares, the Preferred Shares, and the PPCs by a reverse split ratio within a range of two -for-one(2:1) to twenty -for-one(20:1), and (iv) the increase of the share capital of the Company, by way of an ordinary capital increase, by up to 3,500,000 NLS Common Shares (which number is subject to change, depending on the determined par value reduction under Proposal 2(i) and the determined reverse split ratio under Proposal 2(iii), and corresponds to 70,000,000 NLS Common Shares before par value reduction and reverse split), and up to a maximum of CHF 240,000 (which amount is subject to change, depending on the determined par value reduction under Proposal 2(i)), to create the required number of the NLS Common Shares to be issued at the effective time of the Merger to the shareholders of Kadimastem in exchange for their Kadimastem Ordinary Shares. 3.To approve the increase of the share capital of the Company